Role of the Biofield Energy Treated Test Formulation on Different Vital Organ Specific Biomarkers

Journal: Letters in Health and Biological Sciences  Web

Published: 2-Jul-19 Volume: 4 Issue: 1

DOI: 10.15436/2475-6245.19.2519 ISSN: 2475-6245

Authors: William Dean Plikerd, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Mayank Gangwar, and Snehasis Jana

Citation: Plikerd, WD., et al. Role of the Biofield Energy Treated Test Formulation on Different Vital Organ Specific Biomarkers. (2019) Lett Health Biol Sci 4(1): 16-25.

  • 10 Views
  • Downloads

Abstract

The present study was undertaken to evaluate the impact of the Biofield Energy Treated test formulation using cell lines related with vital organs functioning. In vitro cells based assay were performed to study the effects on the bones, heart, liver, lungs, and brain cells. The test formulation and the cell media was divided into two parts; one part was untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, William Dean Plikerd, USA and labeled as the Biofield Energy Treated (BT) test formulation/media. The test formulation was tested against various activities using cell line assay in their specific medium (Med). The test formulation was tested for cell viability, and the results showed that the test formulation at tested concentrations was found safe and non-toxic. Cytoprotective action of the test formulation showed a significant maximum restoration of cell viability by 133.4% (at 1 μg/mL), 65.7% (at 10 μg/mL), and 86.8% (at 10 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group in human cardiac fibroblasts cells (HCF) cells, while improved restoration of cell viability by 97.4% (at 1 μg/mL), 85.7% (at 10 μg/mL), and 81.9% (at 10 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group in HepG2 cells. Cellular restoration in A549 cells was improved by 174.2%, 472.6%, 118%, and 279.2% at 0.1, 1, 10, and 25.5 μg/mL respectively, in the BT-Med + UT-TI group, while 1514%, 1654.8%, 449.8%, and 540.4% improved cellular restoration was reported at 0.1, 1, 10, and 25.5 μg/mL respectively, at BT-Med + BT-TI groups as compared to the untreated test group. ALP activity in MG-63 cells was significantly increased by 93.4% at 50 μg/mL in the UT-Med + BT-TI group, while in Ishikawa cells showed maximum increased ALP activity by 107.4% at 50 μg/mL in the BT-Med + UT-TI group as compared to the untreated group. The maximum percent cellular protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 35.9% at 10 μg/mL in the UT-Med + BT-TI group, while BT-Med + UT-TI group showed increased protection by 69.3% at 1 μg/mL, and improved cellular protection by 119.1% and 44% at 1 and 10 μg/mL respectively, in the BT-Med + BT-TI group as compared to the untreated test group. Alanine amino transferase (ALT) activity was reported in terms of percent cellular protection of HepG2 (liver) cells. Results showed improved HepG2 cells protection (represents decreased ALT activity) by 23.8% (at 10 μg/mL), 98.1% (at 25.5 μg/mL), and 97.6% (at 25 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group. Percentage cellular protection of A549 (lungs) cells (represents increased of SOD activity) was increased by 73.5%, 109.8%, and 97.7% at 0.1 μg/mL in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to untreated group. Serotonin level was significantly increased 68% (at 25 μg/mL), 75.7% (at 0.1 μg/mL), and 57.2% (at 25 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to untreated test group in human neuroblastoma cells (SH-SY5Y). However, the relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 16.4% (at 10 μg/mL), 182% (at 50 μg/mL), and 137.1% (at 50 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in MG-63 cells. In conclusion, Biofield Energy treated test formulation (The Trivedi Effect®) would be significantly useful for multiple organs health that can be used against coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.

Conclusion

Multiple organ health was analyzed using standard cell line assays. The safe concentrations of the test formulation was first analyzed using MTT assay, which showed that the test formulation was found safe and non-toxic against all the tested cell lines. Cytoprotective activity against t-BHP induced cell damage was tested using human cardiac fibroblasts cells (HCF), which showed restoration of cell viability by 133.4% (at 1 μg/mL), 65.7% (at 10 μg/mL), and 86.8% (at 10 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group, while in HepG2 cells the maximum restoration of cell viability was 97.4%, 73%, and 39.4% at 1, 10, and 25 μg/mL respectively, in the UT-Med + BT-TI group, 43.4%, 85.7%, and 49.9% improved cellular restoration at 1, 10 and 25 μg/mL respectively, in the BT-Med + UT-TI, and 81.9% and 28.6% improved cellular restoration at 10 and 25 μg/mL respectively, in the BT-Med + BT-TI group as compared to the untreated test group. In A549 cells, cellular restoration was improved by 174.2%, 472.6%, 118%, and 279.2% at 0.1, 1, 10, and 25.5 μg/mL respectively, in the BTMed + UT-TI group, while 1514%, 1654.8%, 449.8%, and 540.4% improved cellular restoration was reported at 0.1, 1, 10, and 25.5 μg/mL respectively, at BT-Med + BT-TI groups as compared to the untreated test group. Similarly, ALP activity in Ishikawa cells showed significantly increased ALP activity by 10.3% (10 μg/mL), 107.4% (50 μg/mL), and 60.9% (50 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI group, and BT-Med + BT-TI groups respectively, as compared to the UT-Med + UT-TI group. Similarly, ALP activity in MG-63 cells with maximum cellular protection was reported at 93.4% (50 μg/mL), 77.9% (1 μg/mL), 93.2% (50 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI group test groups, respectively, as compared with the untreated test group. LDH activity was significantly decreased and the data was presented in increased percentage cellular protection data, which showed maximum cellular protection by 35.9% (at 10 μg/mL), 69.3% (at 1 μg/mL), and 119.1% (at 1 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI group, and BT-Med + BT-TI groups respectively, as compared to the untreated test group.

ALT activity showed maximum improved cellular protection of HepG2 cells (decreased of ALT activity) by 23.8% (at 10 μg/mL), 98.1% (at 25.5 μg/mL), and 97.6% (at 25 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI group, and BTMed + BT-TI groups respectively, as compared with the untreated test group. SOD activity was significantly increased by 73.5%, 109.8%, and 97.7% in the UT-Med + BT-TI, BT-Med + UT-TI group, and BT-Med + BT-TI groups respectively, at 0.1 μg/mL as compared with the untreated test group. Serotonin level was significantly increased in SH-SY5Y cells by 68% (at 25 μg/mL), 75.7% (at 0.1 μg/mL), and 57.2% (at 25 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared with the untreated test group. However, VDR expression was tested in MG-63 cells, which showed increased RQ of VDR by 16.4%, 182%, and 137.1% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, at 50 μg/mL as compared to the untreated test control group. Thus, this study concluded that the Biofield Energy based test formulation can improve the overall functioning of heart, liver, bones, neuronal, and lungs parameters against any oxidative stress or damage induced by free radicals. Biofield Energy Treatment (The Trivedi Effect®) can be used for the prevention of various types of cardiac disorders such as stroke, thromboembolic disease, congestive heart failure, congenital heart disease, peripheral artery disease, rheumatic heart disease, valvular heart disease, and venous thrombosis, etc. Besides, it would also protect against many hepatic disorders (cirrhosis, liver cancer, hemochromatosis, and Wilson disease), lungs disorders (asthma, chronic bronchitis, emphysema, cystic fibrosis, and pneumonia), and many immune disorders. In addition, this novel test formulation can also be utilized for organ transplants (i.e., kidney, liver, and heart transplants), hormonal imbalance, aging, and various inflammatory and immune-related disease conditions like Asthma, Aplastic Anemia, Graves’ Disease, Dermatitis, Diabetes, Parkinson’s Disease, Myasthenia Gravis, Ulcerative Colitis (UC), Atherosclerosis, etc. to improve overall health and Quality of Life.